药品注册申请号:022255
申请类型:NDA (新药申请)
申请人:UCB INC
申请人全名:UCB INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 VIMPAT LACOSAMIDE SOLUTION;ORAL 10MG/ML Yes Yes AA 2010/04/20 2010/04/20 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/10/16 SUPPL-39(补充) Approval Labeling STANDARD
2023/04/28 SUPPL-32(补充) Approval Efficacy STANDARD
2022/09/30 SUPPL-37(补充) Approval Labeling STANDARD
2022/05/19 SUPPL-36(补充) Approval Labeling STANDARD
2021/10/14 SUPPL-31(补充) Approval Efficacy STANDARD
2021/09/15 SUPPL-33(补充) Approval Labeling STANDARD
2020/11/16 SUPPL-30(补充) Approval Efficacy STANDARD
2020/11/16 SUPPL-27(补充) Approval Efficacy STANDARD
2019/06/11 SUPPL-26(补充) Approval Labeling STANDARD
2019/01/09 SUPPL-23(补充) Approval Efficacy STANDARD
2018/11/11 SUPPL-24(补充) Approval Labeling STANDARD
2017/11/03 SUPPL-22(补充) Approval Efficacy STANDARD
2017/03/24 SUPPL-21(补充) Approval Labeling STANDARD
2016/02/26 SUPPL-17(补充) Approval Manufacturing (CMC) STANDARD
2015/07/09 SUPPL-16(补充) Approval Labeling STANDARD
2014/08/29 SUPPL-13(补充) Approval Efficacy STANDARD
2014/08/29 SUPPL-12(补充) Approval Efficacy STANDARD
2014/08/12 SUPPL-14(补充) Approval Labeling STANDARD
2014/04/11 SUPPL-15(补充) Approval Manufacturing (CMC) STANDARD
2014/01/17 SUPPL-11(补充) Approval Manufacturing (CMC) STANDARD
2014/01/16 SUPPL-9(补充) Approval Labeling UNKNOWN
2013/09/25 SUPPL-5(补充) Approval Labeling STANDARD
2013/09/25 SUPPL-3(补充) Approval Labeling STANDARD
2013/04/17 SUPPL-10(补充) Approval Labeling STANDARD
2013/02/08 SUPPL-2(补充) Approval Labeling STANDARD
2013/02/05 SUPPL-8(补充) Approval Labeling STANDARD
2011/08/10 SUPPL-7(补充) Approval REMS N/A
2010/04/20 ORIG-1(原始申请) Approval Type 3 - New Dosage Form STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 5654301 2014/08/05 Y Y U-914 PDF格式**本条是由Drugfuture回溯的历史信息**
RE38551 2022/03/17 Y U-1567 U-2140 PDF格式**本条是由Drugfuture回溯的历史信息**
RE38551 2022/03/17 Y Y U-1566 U-1567 U-2989 U-2140 U-2990 U-2999 U-914 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 D-188 2026/04/28
NPP 2024/10/14
001 D-143 2017/08/29**本条是由Drugfuture回溯的历史信息**
D-144 2017/08/29**本条是由Drugfuture回溯的历史信息**
I-696 2017/08/29**本条是由Drugfuture回溯的历史信息**
NCE 2013/10/28**本条是由Drugfuture回溯的历史信息**
NPP 2020/11/03**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:LACOSAMIDE 剂型/给药途径:SOLUTION;ORAL 规格:10MG/ML 治疗等效代码:AA
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
022255 001 NDA VIMPAT LACOSAMIDE SOLUTION;ORAL 10MG/ML Prescription Yes Yes AA 2010/04/20 UCB INC
214672 001 ANDA LACOSAMIDE LACOSAMIDE SOLUTION;ORAL 10MG/ML Prescription No No AA 2022/05/19 ALKEM LABS LTD
209301 001 ANDA LACOSAMIDE LACOSAMIDE SOLUTION;ORAL 10MG/ML Prescription No No AA 2022/05/31 HETERO LABS LTD III
216151 001 ANDA LACOSAMIDE LACOSAMIDE SOLUTION;ORAL 10MG/ML Prescription No No AA 2022/08/26 NOVITIUM PHARMA
206355 001 ANDA LACOSAMIDE LACOSAMIDE SOLUTION;ORAL 10MG/ML Prescription No No AA 2022/09/26 APOTEX
216461 001 ANDA LACOSAMIDE LACOSAMIDE SOLUTION;ORAL 10MG/ML Prescription No No AA 2023/02/06 LEADING PHARMA
215379 001 ANDA LACOSAMIDE LACOSAMIDE SOLUTION;ORAL 10MG/ML Prescription No No AA 2023/12/22 MSN
209224 001 ANDA LACOSAMIDE LACOSAMIDE SOLUTION;ORAL 10MG/ML Prescription No No AA 2024/01/24 AUROBINDO PHARMA LTD
204839 001 ANDA LACOSAMIDE LACOSAMIDE SOLUTION;ORAL 10MG/ML Prescription No No AA 2024/03/27 AMNEAL PHARMS
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database